WCM-Q shines light on Qatar's path to ‘global excellence' in cancer care, research
Doha
Researchers at Weill Cornell Medicine-Qatar (WCM-Q) have conducted a comprehensive study of Qatar's pioneering national cancer care and research strategy, highlighting the country's significant achievements in improving prevention, detection and treatment of the disease.
The report, published in the leading UK medical journal Lancet Oncology, notes the remarkable success of Qatar's investments in advanced clinical and research infrastructure, cutting-edge technologies, and recruitment of highly skilled healthcare professionals over the past two decades, which have transformed the country into a regional leader in cancer care.
Areas of particular strength in Qatar's system of cancer care - which has been shaped by the National Cancer Strategy (2010) and the Qatar Cancer Plan (2023-26) - include special expertise in precision and personalized medicine, early detection (based on well-developed screening facilities and schedules), and robustly evidence-based cancer management following diagnosis, leading to improved survival rates.
The research, titled 'Qatar national cancer care and research: pioneering strategies for global health excellence,' also highlights areas where some challenges still exist, including late-stage diagnosis, low health literacy relating to cancer among some demographic groups in Qatar, and data collection and long-term analysis.
WCM-Q's Dr. Lotfi Chouchane, professor of genetic medicine and professor of microbiology and immunology, is the senior author of the paper. The report, and a subsequent paper also published in Lancet Oncology, additionally highlights the potential for establishing beneficial regional and global collaborations on cancer care and research, particularly with Saudi Arabia and Jordan.
This subsequent paper, titled 'Bridging borders for resilience in cancer control in the Middle East: a strategic alliance of Saudia Arabia, Qatar, and Jordan' also provides an epidemiological breakdown of patterns of cancer burden in the three countries. Dr. Murugan Subramanian, senior research associate, is a co-first author of the paper, with Dr. Chouchane serving as a co-senior author.
Other researchers who contributed include Sheikh Dr. Mohammed Bin Hamad Al-Thani, director of the Public Health Department at the Ministry of Public Health and associate professor of Clinical Healthcare Policy and Research at WCM-Q and Qatar University; Dr Salha Bujassoum, senior consultant at the National Centre for Cancer Care and Research; Dr. Khalid Rashid Al-Rumaihi, head of the Department of Urology at Hamad Medical Corporation; and Dr. Hilal Lashuel, research development and innovation advisor to the chairperson of Qatar Foundation and executive director of RDI at the Chairperson's Office.
Dr. Chouchane said: 'This research shows very clearly that the past two decades have been a huge success story for Qatar in its efforts to establish a truly world-class cancer care and innovation infrastructure. Looking ahead, we identified some challenges to overcome in the areas of community health literacy; cultural sensitivities surrounding important cancer-prevention measures; language barriers; data collection, digitization and long-term analysis; issues around healthcare equity; and the growing global challenge of unhealthy lifestyle choices, which can increase cancer risk.
'We can see, however, that Qatar is already taking steps to address many of these challenges, as is shown by the Qatar Cancer Plan 2023-26, developed by the Ministry of Public Health and the National Cancer Governance Board.'
The research also draws attention to Qatar's efforts to prioritize the integration of cutting-edge precision and personalized medicine protocols into clinical practice - a measure which is already having a significant positive impact on survival rates.
He added: 'Precision medicine is one of the most promising areas for cancer research and enhanced patient outcomes, but a limiting factor is that it is dependent on good-quality genomic data matched with good-quality clinical data. Therefore, sharing genomic and clinical data with healthcare systems in neighbouring countries who have populations with similar ethnic backgrounds could provide a dramatic boost for precision oncology in the region.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
16 hours ago
- Qatar Tribune
Doha Municipality enhances food safety at 10th Local Date Festival
Tribune News Network Doha As part of its commitment to enhancing community cooperation, improving the quality of life, and providing healthy and safe food for citizens and residents, Doha Municipality — represented by the Health Control Section of the Municipal Control Department — is participating in the 10th Local Date Festival. The festival is organised by the Ministry of Municipality and Environment and Souq Waqif Management, from July 24 to August 7, 2025. The municipality's participation focuses on conducting intensive health inspections and monitoring campaigns on participating farms and food companies, which display dates and other fruits and food products, to ensure their adherence to sound food handling practices and protect consumers from any potential risks. page 3
Qatar Tribune
26-07-2025
- Qatar Tribune
Veterinary quarantine facilities at Ruwais Port and Hamad Port receive 3-star GSAS certification
Tribune News Network Doha The new veterinary quarantine facilities at Ruwais Port and near Hamad Port have received three-star ratings from the Global Sustainability Assessment System (GSAS). This achievement is a culmination of Qatar's efforts to consolidate environmental sustainability practices within its various development projects, in line with the Qatar National Vision 2030 and its goals to promote green infrastructure. This achievement reflects the Ministry of Municipality's commitment to applying the highest sustainability standards in the design, construction, and operation of veterinary facilities, ensuring a healthy and safe environment and enhancing operational efficiency in accordance with international best practices. The GSAS system is the first integrated sustainability assessment system in the Middle East and North Africa region. It was specifically designed to align with the nature of the region's urban environment. It is the same system used to assess major projects such as the FIFA World Cup Qatar 2022 stadiums and Lusail City. This classification enhances the role of veterinary quarantines in supporting sustainable development goals and enhancing the efficiency of environmental infrastructure across the country. The Ministry of Municipality continues its efforts to enhance the efficiency of veterinary quarantines and expand their operational capabilities, as part of its strategy to develop service infrastructure to serve food security goals and protect society from trans-boundary animal diseases.
Qatar Tribune
23-07-2025
- Qatar Tribune
Sidra Medicine contributes to breakthrough tool for early detection of Type 1 diabetes
Tribune News Network Doha Sidra Medicine, a member of Qatar Foundation, has helped develop an artificial intelligence (AI) powered tool that predicts the risk of developing Type 1 Diabetes (T1D), enabling earlier diagnosis and more targeted care. The tool uses microRNA signals in the blood to detect early biological changes linked to the disease. Published in Nature Medicine, the study titled 'A microRNA-based dynamic risk score for type 1 diabetes' introduces a dynamic risk score based on microRNAs, which are tiny molecules in the blood that reflect changes in the body, including early stress in insulin-producing Beta cells. By analysing data from over 2,800 participants, the researchers found that these molecular signals could identify individuals at high risk of developing T1D long before symptoms appear. Dr. Ammira Akil, principal investigator at Sidra Medicine and director of the Metabolic and Mendelian Disorders Translational Programme, who designed the study, said: 'This study marks a significant advancement in the way we understand and manage autoimmune diseases like Type 1 Diabetes. By combining microRNA profiling with artificial intelligence, we have developed a predictive risk score that can help identify individuals at highest risk, optimise treatment decisions and determine when to intervene. It is a powerful example of how AI and Machine Learning are transforming precision medicine into real-world clinical impact.' Sidra Medicine's contribution to the study was led by the Mendelian and Metabolic Translational Research Programme under the Precision Genomics and Translational Omics Lab. The team played a keyrole in the early laboratory work on primary human insulin-producing cells and conducted critical analyses that helped with the development and validation of the clinical risk score. The study findings complement ongoing efforts at Sidra Medicine, including the DANNA1 cohort, a local foundational population-based registry of individuals with T1D in Qatar that underpin the upcoming national screening programme for early detection and prevention of Type 1 Diabetes. Prof. Khalid Fakhro, chief research officer and chair of the Precision Medicine Programme at Sidra Medicine, said: 'The study findings demonstrate that the microRNA-based dynamic risk score can accurately differentiate between individuals with and without Type 1 Diabetes. It also predicts who may become insulin dependent after an islet cell transplant and identifies patients likely to respond to specific therapies - insights that current clinical markers cannot provide. 'Importantly, this assessment is achievable through a simple, minimally invasive blood test, making it highly promising for routine clinical use. The study also reflects our ongoing commitment to advancing the use of artificial intelligence as a powerful tool to drive earlier diagnosis, more precise treatments, and safer outcomes for patients.' The next phase of the research will focus on validating the findings across broader and more diverse populations and assessing the integration of the dynamic risk score into clinical trials and early intervention strategies. Sidra Medicine will continue to support these efforts through its research programmes and ongoing collaborations. The groundbreaking study was made possible through a multinational collaboration involving experts from Sidra Medicine, Breakthrough T1D, the University of Western Sydney, and the PREDICT T1D Study Group.
